Results 81 to 90 of about 2,938,349 (358)
Ion channel function of polycystin‐2/polycystin‐1 heteromer revealed by structure‐guided mutagenesis
FEBS Letters, EarlyView.Mutations in polycystin‐1 (PC1) or polycystin‐2 (PC2) cause autosomal‐dominant polycystic kidney disease (ADPKD). We generated a novel gain‐of‐function PC2/PC1 heteromeric ion channel by mutating pore‐blocking residues. Moreover, we demonstrated that PC2 will preferentially assemble with PC1 to form heteromeric complexes when PC1 is co‐expressed ...
Tobias Staudner +7 more
wiley +1 more source
Drug Supply Chain Optimization for Adaptive Clinical Trials [PDF]
arXiv, 2023 With increasing interest in adaptive clinical trial designs, challenges are present to drug supply chain management which may offset the benefit of adaptive designs. Thus, it is necessary to develop an optimization tool to facilitate the decision making and analysis of drug supply chain planning.
arxiv
A theoretical framework for estimation of AUCs in complete and incomplete sampling designs. [PDF]
, 2009 Nonclinical in vivo animal studies have to be completed before starting clinical studies of the pharmacokinetic behavior of a drug in humans. The drug exposure in animal studies is often measured by the area under the concentration versus time curve (AUC)
Jaki, Thomas, Wolfsegger, Martin J.
core +1 more source
FEBS Letters, EarlyView.The enzyme 5‐lipoxygenase (5‐LOX) catalyzes the first step in the biosynthesis of leukotrienes (LTs) involved in inflammatory pathophysiology. After cellular stimulation, 5‐LOX translocates to the nucleus, interacting with the 5‐LOX‐activating protein (FLAP) to form LTA4 from arachidonic acid (AA).
Erik Romp +5 more
wiley +1 more source
Scientific Reports, 2017 GPR139 is an orphan G protein-coupled receptor expressed in the brain, in particular in the habenula, hypothalamus and striatum. It has therefore been suggested that GPR139 is a possible target for metabolic disorders and Parkinson’s disease.
Anne Cathrine Nøhr +9 more
doaj +1 more source
Designing the statistically optimal drug for cancer therapy [PDF]
arXiv, 2013 Cancer and healthy cells have distinct distributions of molecular properties and thus respond differently to drugs. Cancer drugs ideally kill cancer cells while limiting harm to healthy cells. However, the inherent variance among cells in both cancer and healthy cell populations increases the difficulty of selective drug action.
arxiv
Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing [PDF]
arXiv, 2020 The 2019 novel coronavirus (SARS-CoV-2) pandemic has resulted in more than a million deaths, high morbidities, and economic distress worldwide. There is an urgent need to identify medications that would treat and prevent novel diseases like the 2019 coronavirus disease (COVID-19).
arxiv
An In-depth Summary of Recent Artificial Intelligence Applications in Drug Design [PDF]
arXiv, 2021 As a promising tool to navigate in the vast chemical space, artificial intelligence (AI) is leveraged for drug design. From the year 2017 to 2021, the number of applications of several recent AI models (i.e. graph neural network (GNN), recurrent neural network (RNN), variation autoencoder (VAE), generative adversarial network (GAN), flow and ...
arxiv
Molecular dynamics in drug design
European Journal of Medicinal Chemistry, 2015 Molecular dynamics (MD) simulations are useful tools for structure-based drug design. We review recent publications in which explicit solvent MD was used at the initial or final stages of high-throughput docking campaigns. In some cases, MD simulations of the protein target have been carried out before docking to generate a conformer of the protein ...
Zhao Hongtao, Caflisch Amedeo
openaire +3 more sources
Molecular Oncology, EarlyView.Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink +6 more
wiley +1 more source